Compare BCYC & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCYC | ORGO |
|---|---|---|
| Founded | 2009 | 1985 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.7M | 348.6M |
| IPO Year | 2019 | 2016 |
| Metric | BCYC | ORGO |
|---|---|---|
| Price | $4.66 | $2.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $13.90 | $8.50 |
| AVG Volume (30 Days) | 386.6K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $4.24 | $2.04 |
| 52 Week High | $9.36 | $7.08 |
| Indicator | BCYC | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 47.52 |
| Support Level | $4.52 | $2.26 |
| Resistance Level | $5.41 | $2.63 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 20.14 | 56.52 |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.